A traditional Chinese medicine composition and its preparation method, a medicine box, and its application.

By combining a traditional Chinese medicine composition with highly active ingredients extracted from Gnaphalium affine and then using benzbromarone, the problems of low active ingredient content and hepatotoxicity in existing technologies have been solved, achieving significant effects in lowering uric acid and protecting the kidneys.

CN114053321BActive Publication Date: 2026-11-10SHANGHAI INST OF PHARMA IND CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202010761535.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-07-31
Publication Date
2026-11-10
Estimated Expiration
2040-07-31

AI Technical Summary

Technical Problem

The existing traditional Chinese medicine compositions contain low levels of active ingredients from *Gnaphalium affine* extract, and no existing traditional Chinese medicine composition can guarantee efficacy and reduce hepatotoxicity while reducing the dosage of benzbromarone.

Method used

A traditional Chinese medicine composition is extracted from Gnaphalium affine using a specific process, including extraction with 50-80% ethanol aqueous solution, petroleum ether, ethyl acetate and water-saturated n-butanol, followed by concentration and drying, to obtain a traditional Chinese medicine composition with an active ingredient content of more than 50%, which is then used in conjunction with benzbromarone.

Benefits of technology

It improves the content and bioavailability of active ingredients in traditional Chinese medicine compositions, significantly reduces uric acid levels, enhances the therapeutic effect on chronic hyperuricemia and hyperuricemic nephropathy, and reduces liver damage caused by benzbromarone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114053321B_ABST
    Figure CN114053321B_ABST
Patent Text Reader

Abstract

This invention discloses a traditional Chinese medicine composition, its preparation method, a medicine box, and its application. The preparation method of the traditional Chinese medicine composition includes the following steps: S1. Mixing *Gnaphalium affine* with an ethanol-water solution to obtain an extract; wherein the ethanol-water solution is an ethanol-water solution with a volume percentage of 50%–80%; S2. Concentrating the extract to obtain a concentrate; S3. Extracting the concentrate with petroleum ether to obtain an aqueous phase I; extracting the aqueous phase I with ethyl acetate to obtain an aqueous phase II and an ethyl acetate phase; extracting the aqueous phase II with water-saturated n-butanol to obtain a water-saturated n-butanol phase; collecting the ethyl acetate phase and the water-saturated n-butanol phase. The traditional Chinese medicine composition obtained from *Gnaphalium affine* extract of this invention has high levels of active ingredients and exhibits excellent therapeutic effects on chronic hyperuricemia and hyperuricemic nephropathy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a traditional Chinese medicine composition, its preparation method, a medicine box, and its application. Background Technology

[0002] Hyperuricemia is defined as a condition in which fasting serum uric acid levels are measured twice on different days under normal purine diet conditions, with males having serum uric acid levels higher than 420 μmol / L (7 mg / dL) and females higher than 357 μmol / L (6 mg / dL). Currently, the treatment of hyperuricemia mainly relies on chemical drugs, which can be classified into three categories based on their mechanism of action and target: allopurinol, a representative drug that inhibits uric acid synthesis, but allopurinol is prone to causing serious adverse reactions; benzbromarone and probenecid, representative drugs that promote uric acid excretion, often accompanied by adverse reactions such as liver damage and rash; and drugs that promote uric acid decomposition (such as raburicase), which are prone to causing allergic reactions and producing antibodies, thus becoming ineffective (Ma Jinkui, Zhang Hongbin. Research progress on hyperuricemia and its treatment drugs [J]. Guangdong Medical Journal, 2018, 7(39):262-267).

[0003] As a drug that promotes uric acid excretion, benzbromarone's hepatotoxicity is receiving increasing attention. It has been reported that the hepatotoxicity induced by benzbromarone is related to its 1'- or 6-hydroxybenzbromarone metabolites, which are converted by cytochrome P450 3A4 (CYP3A4) or 2C9 (CYP2C9), respectively (Kobayashi K, Kajiwara E, Ishikawa M, et al. Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes[J]. Biopharmaceutics & drug disposition, 2012, 33(8):466-473. Kobayashi K, Kajiwara E, Ishikawa M, et al. Cytotoxic Effects of Benzbromarone and Its 1'-Hydroxy Metabolite in Human Hepatocarcinoma FLC4Cells Cultured on Micro-spaceCell Culture Plates[J]. Drug Metabolism and Pharmacokinetics, 2012, 28(3):265-268.). These two metabolites may be further oxidized to dihydroxy products in liver microsomes, which in turn form adducts with glutathione, affecting the function and structure of hepatocyte mitochondria and thus producing hepatotoxicity (Mcdonald MG, Rettie AE. Sequential Metabolism and Bioactivation of the Hepatotoxin Benzbromarone: Formation of Glutathione Adducts From a Catechol Intermediate[J]. Chemical Research in Toxicology, 2007, 20(12): 1833-1842.).

[0004] Gnaphalium affine, also known as cudweed, is a plant belonging to the genus Gnaphalium in the family Asteraceae. It has a slightly sweet taste and neutral properties, and is used to dispel wind, resolve phlegm, and eliminate turbidity. Existing literature discloses that a 95% ethanol extract is effective in treating hyperuricemia and acute gouty arthritis (Zhang HJ, Li LN, Zhou J, et al. Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis[J]. Journal of Ethnopharmacology, 2017, 203:304-311.); additionally, a 60% ethanol extract is also effective in treating hyperuricemia (CN101925361A, WO2009093584JA). However, the publicly available and reported extracts of *Gnaphalium affine* for lowering uric acid are not ideal for pharmaceutical purposes. They suffer from low levels of active ingredients, failing to meet current regulatory requirements for pharmaceuticals (the active ingredient mass fraction must be higher than 50%).

[0005] In existing technologies, there are methods for combining benzbromarone with traditional Chinese medicine compound formulas. Besides enhancing the mechanism of action and improving the efficacy of uric acid-lowering drugs, their combined use also shows better renal protection. However, there is still no existing traditional Chinese medicine composition that can maintain efficacy and reduce the hepatotoxicity of benzbromarone while reducing its dosage. Summary of the Invention

[0006] This invention addresses the shortcomings of existing technologies, such as the low content of active ingredients in *Gnaphalium affine* extract and the lack of a suitable traditional Chinese medicine composition that can maintain efficacy and reduce the hepatotoxicity of benzbromarone while reducing its dosage. The invention provides a traditional Chinese medicine composition, its preparation method, a kit, and its application. The traditional Chinese medicine composition obtained from *Gnaphalium affine* extract has a high content of active ingredients (>50 wt%) and exhibits excellent therapeutic effects on chronic hyperuricemia and hyperuricemic nephropathy.

[0007] This invention provides a method for preparing a traditional Chinese medicine composition, which includes the following steps:

[0008] S1. Mix cudweed with an ethanol-water solution and extract to obtain an extract;

[0009] Wherein, the ethanol aqueous solution is an ethanol aqueous solution with a volume percentage of 50% to 80%;

[0010] S2. Concentrate the extract to obtain a concentrated solution;

[0011] S3. Extract the concentrate with petroleum ether to obtain aqueous phase one; extract aqueous phase one with ethyl acetate to obtain aqueous phase two and ethyl acetate phase; extract aqueous phase two with water-saturated n-butanol to obtain water-saturated n-butanol phase; collect the ethyl acetate phase and the water-saturated n-butanol phase.

[0012] In S1, the ethanol aqueous solution can be a conventional ethanol aqueous solution with a volume percentage of 50% to 80%, preferably a ethanol aqueous solution with a volume percentage of 60%.

[0013] In S1, the mass-to-volume ratio of the cudweed to the ethanol aqueous solution can be the same as the ratio of raw material to solvent used in conventional phytochemical extraction, preferably 1:10 to 1:20 kg / L, and more preferably 1:10 to 1:15 kg / L.

[0014] In S1, the *Gnaphalium affine* can be the conventional *Gnaphalium affine* in the art, preferably *Gnaphalium affine* that has been air-dried. In the art, air-drying generally refers to placing the medicinal material in a cool, shady place indoors, outdoors, or in a greenhouse, using flowing air to blow away moisture to achieve the purpose of drying. The "air-dried *Gnaphalium affine*" mentioned in this invention generally refers to *Gnaphalium affine* with a moisture content of 3-5% by mass, for example, about 4%.

[0015] In S1, the extraction operations and conditions can be conventional in the field.

[0016] The extraction temperature is preferably 50–100°C, more preferably 70–100°C, and even more preferably 70–80°C.

[0017] The number of extractions can be selected according to conventional methods in the field, preferably 2 to 4 times, and more preferably 3 to 4 times.

[0018] In the extraction process, the extraction time for a single extraction is preferably 1 to 2 hours.

[0019] In S2, the concentration operation and conditions can be conventional in the art, generally vacuum concentration.

[0020] The temperature of the vacuum concentration is preferably 50-70°C, for example 60°C.

[0021] In S2, the mass-to-volume ratio of the cudweed in S1 to the concentrated liquid in S2 is preferably 1:0.5 to 1:2 kg / L, more preferably 1:0.5 to 1:1 kg / L.

[0022] In S3, the amount of petroleum ether used can be conventional in the art. Preferably, the volume ratio of the concentrate to the petroleum ether is 1:1 to 1:2.

[0023] In S3, the number of petroleum ether extractions can be conventional in the art, preferably 2 to 4 times, and more preferably 3 times.

[0024] In S3, the petroleum ether is preferably a petroleum ether with a boiling range of 60–90°C.

[0025] In S3, the amount of ethyl acetate used can be conventional in the art. Preferably, the volume ratio of the aqueous phase to the ethyl acetate is 1:1 to 1:2.

[0026] In S3, the number of ethyl acetate extractions can be conventional in the art, preferably 2 to 4 times, and more preferably 3 times.

[0027] In S3, the water-saturated n-butanol can be water-saturated n-butanol commonly used in the art. The preparation method is generally to mix n-butanol and distilled water at room temperature (0-40°C) (mixing volume ratio of 1:1), shake, mix well, and let stand overnight. The resulting mixture will separate into layers, with the upper layer being water-saturated n-butanol.

[0028] In S3, the amount of water-saturated n-butanol used can be conventional in the art. Preferably, the volume ratio of the aqueous phase II to the water-saturated n-butanol is 1:1 to 1:2.

[0029] In S3, the number of water-saturated n-butanol extractions can be conventional in the art, preferably 2 to 4 times, and more preferably 3 times.

[0030] In this invention, the preparation method further includes: S4. concentrating and drying the mixture of the ethyl acetate phase and the water-saturated n-butanol phase; or concentrating and drying the ethyl acetate phase and the water-saturated n-butanol phase separately and then mixing them.

[0031] In S4, the concentration is preferably vacuum concentration, and generally vacuum concentration to dryness is sufficient.

[0032] The temperature of the vacuum concentration is 40–80°C.

[0033] The present invention also provides a traditional Chinese medicine composition, which is prepared by the method described above for preparing traditional Chinese medicine compositions.

[0034] Preferably, the content of active ingredients in the traditional Chinese medicine composition is 50% or more, more preferably 54.12% to 57.81%; wherein all percentages are by mass.

[0035] Preferably, the active ingredients of the traditional Chinese medicine composition include: apigenin, luteolin, luteolin-4'-O-glucoside, gingerol, quercetin, caffeic acid, methyl caffeate, and gnaphaffine. A. One or more of the following: methyl 3,5-di-O-caffeoylquinic acid, 3,4,5-tri-O-caffeoylquinic acid, methyl 1,4-di-O-caffeoylquinic acid, 1,3,5-tri-O-caffeoylquinic acid, 1,3,4-tri-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, 3,4-di-O-caffeoylquinic acid, 1,4-di-O-caffeoylquinic acid, 1-O-caffeoyl glucose, 4,6,4'-trihydroxy-2-methoxychalcone, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin), chlorogenic acid, 5-O-caffeoylquinic acid, and ethyl caffeate.

[0036] More preferably, the active ingredients of the traditional Chinese medicine composition include: 0.1%–5.5% apigenin, 0.5%–9.8% luteolin, 0.2%–10.0% luteolin-4'-O-glucoside, 0.01%–2.2% galangin, 0.02%–1.4% quercetin, 0.8%–3.9% caffeic acid, 0.1%–13.0% methyl caffeate, and 0.1%–3.3% gnaphaffine. A. 0.01%–0.8% methyl 3,5-di-O-caffeoylquinic acid, 0.2%–10.4% 3,4,5-tri-O-caffeoylquinic acid, 0.01%–0.5% methyl 1,4-di-O-caffeoylquinic acid, 0.03%–9.5% 1,3,5-tri-O-caffeoylquinic acid, 0.2%–12.8% 1,3,4-tri-O-caffeoylquinic acid, 0.3%–6.5% 3,5-di-O-caffeoylquinic acid, 0.1%–5.2% 3,4-di-O-caffeoylquinic acid, 0.1%–0.2% methyl 3,5-di-O-caffeoylquinic acid, 0.1% methyl 3,4-di-O-caffeoylquinic acid, 0.1% methyl 3,5-di-O-caffeoylquinic acid, 0.2%–10.4% methyl 3,4 ... 1,4-di-O-caffeoylquinic acid, 1.5% to 3.7% 1-O-caffeoyl glucose, 0.06% to 5.2% 4,6,4'-trihydroxy-2-methoxychalcone, 0.1% to 3.8% 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin), 0.2% to 2.9% chlorogenic acid, 0.4% to 4.1% 5-O-caffeoylquinic acid, and 0.1% to 1.5% ethyl caffeate; all percentages are by weight.

[0037] The present invention also provides a medicine box set, which includes medicine box A and medicine box B, wherein medicine box A is the traditional Chinese medicine composition as described above, and medicine box B is benzbromarone.

[0038] The medicine box A and the medicine box B can be used in two ways: medicine box A can be used first and then medicine box B can be used, or medicine box B can be used first and then medicine box A can be used, depending on the actual needs of the specific application.

[0039] Preferably, the mass ratio of medicine box A to medicine box B is greater than or equal to 9:1, more preferably greater than 48:1, and even more preferably 100:1 to 200:1.

[0040] The present invention also provides the use of the traditional Chinese medicine composition as described above or the medicine kit as described above in the preparation of a medicine for treating chronic hyperuricemia or hyperuricemic nephropathy.

[0041] Preferably, when the traditional Chinese medicine composition is used alone, the daily dosage is 71-143 mg / kg (i.e., 5-10 g for a 70 kg adult).

[0042] Preferably, when the kit is in use, the daily dosage of the kit B is 0.35–0.72 mg / kg (i.e., 25–50 mg for a 70 kg adult).

[0043] Preferably, when the kit is in use, the daily dosage of kit A is 35–143 mg / kg (i.e., 2.5–5 g for a 70 kg adult).

[0044] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0045] The reagents and raw materials used in this invention are all commercially available.

[0046] The positive and progressive effects of this invention are as follows:

[0047] This invention relates to a traditional Chinese medicine composition extracted from *Gnaphalium affine*, which exhibits high levels of active ingredients and interactions among its components. This composition demonstrates excellent therapeutic effects on chronic hyperuricemia and hyperuricemic nephropathy, improving the bioavailability of the active compounds and prolonging the drug's duration of action. Furthermore, *Gnaphalium affine* is abundant in wild resources and inexpensive, indicating significant development potential.

[0048] The traditional Chinese medicine composition of this invention can be used in combination with benzbromarone, with stable efficacy (significant uric acid-lowering and renal protective effects). Compared with benzbromarone alone, the combination not only enhances the treatment effect on chronic hyperuricemia and hyperuricemic nephropathy, but also significantly reduces uric acid levels; and significantly inhibits the liver damage caused by benzbromarone, thus reducing its toxicity. In combination, the dosage of benzbromarone can be reduced, improving safety while maintaining or even enhancing efficacy. Attached Figure Description

[0049] Figure 1 The effects of oral administration of the traditional Chinese medicine compositions in Examples 1-3 on serum uric acid levels in rats with chronic hyperuricemia and nephropathy were investigated. Compared with the normal group: ***P<0.001, indicating extremely significant statistical differences; compared with the hyperuricemia model group: ###P<0.001, ##P<0.01, indicating extremely significant statistical differences.

[0050] Figure 2 The effects of oral administration of the traditional Chinese medicine compositions in Examples 1-3 on serum creatinine levels in rats with chronic hyperuricemia nephropathy were investigated. Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the hyperuricemia model group: ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0051] Figure 3 The effects of oral administration of the traditional Chinese medicine compositions in Examples 1-3 on serum urea nitrogen levels in rats with chronic hyperuricemia nephropathy were investigated. Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the hyperuricemia model group: ##P<0.01, indicating extremely significant statistical differences.

[0052] Figure 4 The effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum AST levels were investigated. Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; *P<0.05, indicating significant statistical differences. Compared with the liver injury group (benzbromarone administration group): ###P<0.01, ##P<0.01, indicating extremely significant statistical differences; #P<0.05, indicating significant statistical differences.

[0053] Figure 5 The effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum ALT levels were investigated. Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the liver injury group (benzbromarone administration group): ###P<0.01, ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0054] Figure 6 The effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum uric acid levels were investigated. Compared with the normal group: ***P<0.001; compared with the hyperuricemia model group: ###P<0.01, ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0055] Figure 7 This is the HPLC chromatogram of Example 1. Detailed Implementation

[0056] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.

[0057] In the following examples, after the traditional Chinese medicine composition was prepared, the active ingredients and their contents were tested according to the following methods:

[0058] (1) Accurately weigh apigenin, luteolin, luteolin-4'-O-glucoside, gingerol, quercetin, caffeic acid, methyl caffeate, and gnaphaffine. A. Methyl 3,5-di-O-caffeoylquinic acid, 3,4,5-tri-O-caffeoylquinic acid, methyl 1,4-di-O-caffeoylquinic acid, 1,3,5-tri-O-caffeoylquinic acid, 1,3,4-tri-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, 3,4-dicaffeoylquinic acid, 1,4-di-O-caffeoylquinic acid, 1-O-caffeoylglucose, 4,6,4'-trihydroxy-2-methoxychalcone, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin), chlorogenic acid, 5-O-caffeoylquinic acid, and ethyl caffeate reference standards were prepared into a standard solution in methanol.

[0059] (2) Accurately weigh approximately 30.0 mg of the traditional Chinese medicine composition, dissolve it in methanol using ultrasound, cool to room temperature, and then dilute to 10 mL to obtain the test solution. The test solution was analyzed using high-performance liquid chromatography (HPLC) under the following chromatographic conditions:

[0060] UFLC-DAD detection; Pump: Shimadzu LC-20AD XR; Autosampler: SIL-20A XR; Detector: SPD-M20A; Column oven: CTO-20A;

[0061] Column: Agilent Zorbax RRHD Eclipse XDB-C18, 2.1×150mm, 1.8μm;

[0062] Mobile phase A: H₂O + 0.2% formic acid (volume percentage); Mobile phase B: Acetonitrile;

[0063] Flow rate: 0.3 mL / min; Column temperature: 40℃; PDA: 200-400 nm; Detection wavelength: 280 nm; Injection volume: 2 μL;

[0064] Gradient elution, the gradient elution procedure is as follows (% represents volume percentage):

[0065] time Mobile phase A Mobile phase B 0-5min 88% 12% 5-10 min 88%-85% 12-15% 10-15min 85% 15% 15-20min 85%-80% 15-20% 20-30min 80%-70% 20-30% 30-40min 70%-0% 30-100% 40-45min 0% 100% 45-53min 88% 12%

[0066] (3) Compare the chromatogram obtained from the test with the chromatogram obtained from the standard solution.

[0067] Taking Example 1 as an example, such as Figure 7 As shown. Among them, Figure 7 The components corresponding to serial numbers 1-22 are as follows:

[0068] Apigenin (1), Luteolin (2), Luteolin-4'-O-glucoside (3), Gingerol (4), Quercetin (5), Caffeic acid (6), Methyl caffeate (7), Gnaphaffine A (8), Methyl 3,5-di-O-caffeoylquinic acid (9), 3,4,5-tri-O-caffeoylquinic acid (10), Methyl 1,4-di-O-caffeoylquinic acid (11), 1,3,5-tri-O-caffeoylquinic acid (12), 1,3,4-tri-O-caffeoylquinic acid (13), 3,5-di-O-caffeoylquinic acid (14), 3,4-dicaffeoylquinic acid (15) 1,4-Di-O-caffeoylquinic acid (16), 1-O-caffeoyl glucose (17), 4,6,4'-trihydroxy-2-methoxychalcone (18), 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin) (19), chlorogenic acid (20), 5-O-caffeoylquinic acid (21), ethyl caffeate (22).

[0069] Example 1

[0070] (1) After the air-dried cudweed (origin 1: Shangxi Town, Yiwu, Zhejiang) is cut into sections, 5 kg is weighed and mixed with 75 L of ethanol aqueous solution with a volume percentage of 60% (1:15, kg / L). The mixture is heated to 100℃ and refluxed for extraction 4 times, 2 hours each time. The extracts are then combined.

[0071] (2) The extract was concentrated under reduced pressure (60℃) to 5L (the mass-volume ratio of medicinal material to concentrate was 1:1kg / L) to obtain the concentrate.

[0072] (3) Add petroleum ether with a boiling range of 60-90℃ to the concentrate and extract three times, with the volume ratio of concentrate to petroleum ether being 1:1 each time. Discard the petroleum ether phase to obtain aqueous phase one (5L). Add ethyl acetate to aqueous phase one and extract three times, with the volume ratio of aqueous phase one to ethyl acetate being 1:1 each time. After extraction, obtain aqueous phase two (5L). Add water-saturated n-butanol to aqueous phase two and extract three times, with the volume ratio of aqueous phase two to water-saturated n-butanol being 1:1 each time.

[0073] (4) Combine the above ethyl acetate phase and water-saturated n-butanol phase, concentrate under reduced pressure (60°C) to dryness, and obtain 228.7g of the traditional Chinese medicine composition of Example 1.

[0074] The active ingredients of the traditional Chinese medicine composition in Example 1 are as follows (all percentages below are by mass):

[0075] Apigenin 0.2%, luteolin 0.8%, luteolin-4'-O-glucoside 5.8%, galangin 0.01%, quercetin 0.02%, caffeic acid 2.0%, methyl caffeate 13.0%, Gnaphaffine A 3.3%, methyl 3,5-di-O-caffeoylquinic acid 0.8%, 3,4,5-tri-O-caffeoylquinic acid 10.4%, methyl 1,4-di-O-caffeoylquinic acid 0.3%, 1,3,5-tri-O-caffeoylquinic acid 0.03%, 1,3,4-tri-O-caffeoylquinic acid 0.2%, 3,5-di-O-caffeoylquinic acid 0.3%, 3,4-di-O-caffeoylquinic acid 3 The active ingredients are: 0.6%, 1,4-di-O-caffeoylquinic acid 2.8%, 1-O-caffeoyl glucose 1.5%, 4,6,4'-trihydroxy-2-methoxychalcone 0.06%, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin) 3.8%, chlorogenic acid 2.9%, 5-O-caffeoylquinic acid 2.2%, and ethyl caffeate 0.1%. The total content of active ingredients is 54.12%.

[0076] Example 2

[0077] (1) After air-drying, cut the Gnaphalium affine (origin 2: Houxi Town, Quzhou, Zhejiang) into sections, weigh 0.6 kg, mix with 6 L of 50% ethanol aqueous solution (1:10, kg / L), heat to 100℃, reflux extract 3 times, 2 h each time, and combine the extracts.

[0078] (2) The extract was concentrated under reduced pressure (70℃) to 1.2L (the mass-volume ratio of medicinal material to concentrate was 1:2kg / L) to obtain the concentrate.

[0079] (3) Extract the concentrate twice with petroleum ether (boiling range 60–90 °C), each time with a volume ratio of concentrate to petroleum ether of 1:2. Discard the petroleum ether phase to obtain aqueous phase one (1.2 L). Add ethyl acetate to aqueous phase one and extract twice, each time with a volume ratio of aqueous phase one to ethyl acetate of 1:2, to obtain aqueous phase two (1.2 L). Add water-saturated n-butanol to aqueous phase two and extract twice, each time with a volume ratio of aqueous phase two to water-saturated n-butanol of 1:2.

[0080] (4) Combine the above ethyl acetate phase and water-saturated n-butanol phase, concentrate under reduced pressure (60℃) to dryness, and obtain 23.9g of effective substance concentrate of Gnaphalium affine.

[0081] The active ingredients of the traditional Chinese medicine composition in Example 2 are as follows (all percentages below are by mass):

[0082] Apigenin 0.1%, luteolin 9.8%, luteolin-4'-O-glucoside 0.2%, galangin 0.6%, quercetin 1.4%, caffeic acid 0.8%, methyl caffeate 0.8%, Gnaphaffine A 1.8%, methyl 3,5-di-O-caffeoylquinic acid 0.1%, 3,4,5-tri-O-caffeoylquinic acid 1.2%, methyl 1,4-di-O-caffeoylquinic acid 0.01%, 1,3,5-tri-O-caffeoylquinic acid 0.9%, 1,3,4-tri-O-caffeoylquinic acid 12.8%, 3,5-di-O-caffeoylquinic acid 0.8%, 3,4-di-O-caffeoylquinic acid The active ingredients are: 5.2%, 1,4-di-O-caffeoylquinic acid 7.6%, 1-O-caffeoyl glucose 3.7%, 4,6,4'-trihydroxy-2-methoxychalcone 5.2%, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin) 0.1%, chlorogenic acid 0.2%, 5-O-caffeoylquinic acid 4.1%, and ethyl caffeate 0.4%. The total content of active ingredients is 57.81%.

[0083] Example 3

[0084] (1) After air-drying, cut the Gnaphalium affine (origin 2: Houxi Town, Quzhou, Zhejiang) into sections, weigh 2 kg, mix with 40 L of 80% ethanol aqueous solution (1:20, kg / L), heat to 100℃, reflux extract twice, 2 h each time, and combine the extracts.

[0085] (2) The extract is concentrated under reduced pressure (50℃) to 1L (the mass-volume ratio of medicinal material to concentrate is 1:0.5kg / L) to obtain the concentrate.

[0086] (3) Extract the concentrate four times with petroleum ether (boiling range 60–90 °C), with a volume ratio of concentrate to petroleum ether of 1:1 each time. Discard the petroleum ether phase to obtain aqueous phase one (1 L). Add ethyl acetate to aqueous phase one and extract four times, with a volume ratio of aqueous phase one to ethyl acetate of 1:1 each time. Obtain aqueous phase two (1 L) after extraction. Add water-saturated n-butanol to aqueous phase two and extract four times, with a volume ratio of aqueous phase two to water-saturated n-butanol of 1:1 each time.

[0087] (4) Combine the above ethyl acetate phase and water-saturated n-butanol phase, concentrate under reduced pressure (60℃) to dryness, and obtain 74.6g of effective substance concentrate of Gnaphalium affine.

[0088] The active ingredients of the traditional Chinese medicine composition of Example 3 are as follows (all the percentages below are mass percentages):

[0089] Apigenin 5.5%, luteolin 0.5%, luteolin-4'-O-glucoside 10.0%, homogingerol 2.2%, quercetin 0.1%, caffeic acid 3.9%, methyl caffeate 0.1%, Gnaphaffine A 0.1%, methyl 3,5-di-O-caffeoylquinate 0.01%, 3,4,5-tri-O-caffeoylquinic acid 0.2%, methyl 1,4-di-O-caffeoylquinate 0.5%, 1,3,5-tri-O-caffeoylquinic acid 9.5%, 1,3,4-tri-O-caffeoylquinic acid 8.4%, 3,5-di-O-caffeoylquinic acid 6.5%, 3,4-di-O-caffeoylquinic acid 0.1%, 1,4-di-O-caffeoylquinic acid 0.1%, 1-O-caffeoylglucose 3.5%, 4,6,4'-trihydroxy-2-methoxychalcone 1.1%, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside (Gnaphalin) 0.1%, chlorogenic acid 2.6%, 5-O-caffeoylquinic acid 0.4%, ethyl caffeate 1.5%. The total content of active ingredients is 56.91%.

[0090] Effect Example 1

[0091] In Effect Example 1 of the present invention, 48 SD rats (200±20g, purchased from Shanghai Sippr-BK Laboratory Animal Co., Ltd.) were used, and were raised in the Laboratory Animal Center of China State Institute of Pharmaceutical Industry. The breeding standards are as follows: room temperature 22±2℃, relative humidity 50±10%, 12h day-night alternation, and standard laboratory feed and water are provided. The animals were fasted for 12h before the test, with free access to water. All animal experiments comply with the guidelines for the care and use of laboratory animals, and are approved by the Animal Ethics Committee of China State Institute of Pharmaceutical Industry (Laboratory Animal Production License No.: SCXK (Shanghai) 2019-0006, Animal Quality Certificate No. 20190006006257).

[0092] 1. Experimental method

[0093] (1) Hyperuricemic nephropathy rat model and administration method

[0094] Those skilled in the art know that a 5g dose for a 70kg adult corresponds to a 450mg / kg dose for rats.

[0095] Forty-eight SD rats were randomly divided into four groups of eight: a control group (NC), a hyperuricemic nephropathy model group (HN), a benzbromarone 10 mg / kg (BBR) group, an Example 1 (450 mg / kg) group, an Example 2 (450 mg / kg) group, and an Example 3 (450 mg / kg) group. The drug administration volume for each group was 0.1 mL / 10 g. Hyperuricemic nephropathy was induced by gavage with potassium oxonate (1.5 g / kg) and adenine (0.1 g / kg). Three days after modeling, all groups received the drugs continuously. The control group received the same volume of 0.5% CMC-Na by gavage. Blood was collected from the orbital sinus every 7 days (days 7, 14, 21, and 28) one hour after the last gavage administration. Serum was separated and stored at -20°C.

[0096] (2) Effects of traditional Chinese medicine compositions on serum uric acid levels

[0097] Before the experiment, the serum sample was thawed at 4℃ for 30 min. 50 uL of serum was accurately pipetted and 100 uL of methanol solution was added to precipitate the protein. The mixture was vortexed for 1 min and centrifuged at 14000 rpm for 10 min at 4℃. 100 uL of the supernatant was collected for analysis.

[0098] Serum uric acid levels were determined by HPLC; mobile phase A was 0.5% acetic acid in water; mobile phase B was methanol. Gradient elution was used, and the gradient elution program was as follows (% represents volume percentage):

[0099] time Mobile phase A Mobile phase B 0-10min 90% 10% 10-20 min 0% 100% 20-30min 90% 10% 45-53min 88% 12%

[0100] The flow rate was 1 mL / min; the column temperature was 30℃; the detection wavelength was 288 nm; the injection volume was 10 μL; and the chromatographic column was a Dikma Platisil 5 μm ODS 250*4.6 mm.

[0101] (3) Effects of traditional Chinese medicine composition on serum creatinine and uric acid nitrogen

[0102] Serum creatinine levels were determined using a Hitachi 7080 automated biochemical analyzer (HITACHI, Japan), and serum urea nitrogen levels were determined using a UV-2600 ultraviolet spectrophotometer (SHIMADZU, Japan). Specific operations were performed according to the manufacturer's instructions and instrument operating procedures.

[0103] II. Experimental Results

[0104] (1) The uric acid-lowering effect of the traditional Chinese medicine composition is as follows: Figure 1 As shown in Table 1 below,

[0105] Table 1. Changes in serum uric acid levels (mg / L) in different groups during weeks 1–4.

[0106] week Normal group NC Model group HN Example 1 Example 2 Example 3 Benzbromarone group BBR 1 80.72±6.68 164.53±25.72*** 157.38±15.05 158.15±15.70 154.50±13.99 155.55±22.71 2 89.20±4.03 255.92±18.00*** 268.21±42.94 269.25±34.38 264.72±25.84 260.18±27.81 3 92.72±5.66 213.04±7.38*** 175.79±27.50## 175.36±27.61## 179.06±19.21### 192.66±21.78 4 89.20±6.80 258.31±21.72*** 191.13±43.71### 196.57±48.83## 197.02±39.07## 204.73±13.02###

[0107] Note: Compared with the normal group: ***P<0.001, indicating extremely significant statistical difference; compared with the hyperuricemia model group: ###P<0.001, ##P<0.01, indicating extremely significant statistical difference.

[0108] The results showed that one week after modeling, the serum uric acid level in the model group was significantly higher than that in the normal group (P<0.001), indicating that the hyperuricemia model was successfully established. After three weeks of continuous administration, the serum uric acid level in the treatment group began to decrease compared with the model group (P<0.01, P<0.01, P<0.001). After four weeks of continuous administration, the serum uric acid level in the treatment group was significantly lower than that in the model group (P<0.001, P<0.01, P<0.01), indicating that the traditional Chinese medicine composition (450mg / kg) in Examples 1-3 has a uric acid-lowering effect and its activity is comparable to that of benzbromarone (10mg / kg).

[0109] (2) Results of the renal protective effect of the traditional Chinese medicine composition as follows Figure 2 , Figure 3 As shown in Tables 2 and 3, the results indicated that one week after modeling, serum creatinine and blood urea nitrogen levels in the model group began to increase compared to the normal group (P<0.01, P<0.001). In the second week after modeling, serum creatinine and blood urea nitrogen levels in the model group were significantly higher than those in the normal group (P<0.001, P<0.001), indicating that chronic hyperuricemia can cause kidney damage. With continuous administration, starting from the second week, serum creatinine and blood urea nitrogen levels in the herbal composition group were significantly lower than those in the model group, while there was no significant difference between the benzbromarone group and the model group, indicating that the herbal compositions in Examples 1-3 have renal protective properties. However, benzbromarone does not have a renal protective effect.

[0110] Table 2. Changes in serum creatinine levels (μmol / L) in different groups during weeks 1–4.

[0111]

[0112]

[0113] Note: Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the hyperuricemia model group: ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0114] Table 3. Changes in serum urea nitrogen levels (mmol / L) in different groups during weeks 1–4.

[0115] week Normal group NC Model group HN Example 1 Example 2 Example 3 Benzbromarone group BBR 1 7.38±0.98 9.44±1.16** 10.46±1.32 10.36±1.26 10.42±1.08 9.61±1.57 2 8.52±0.55 13.12±1.59*** 10.36±1.36## 10.51±1.31## 10.53±1.06## 11.90±0.68 3 9.17±1.28 13.57±1.01*** 11.59±2.15 11.62±2.23 11.19±1.50## 13.45±1.37 4 10.03±0.42 14.82±0.75*** 13.70±0.30## 13.92±0.52 14.04±0.53 14.31±0.88

[0116] Note: Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the hyperuricemia model group: ##P<0.01, indicating extremely significant statistical differences.

[0117] Example 2

[0118] The results of the toxicity reduction effect of the combined use of traditional Chinese medicine composition and benzbromarone are as follows:

[0119] In vivo animal experiments have demonstrated that the combined application of traditional Chinese medicine composition and benzbromarone can significantly reduce the hepatotoxicity caused by benzbromarone in rats with hyperuricemia nephropathy induced by potassium oxonate and adenine.

[0120] (1) Establishment of liver injury model and administration method

[0121] Fifty-six SD rats (using the same manufacturer and feeding standards as in Example 1) were randomly divided into four groups of eight: a blank (NC) group, a hyperuricemic nephropathy model (HN) group, Example 1 group (450 mg / kg), a hepatotoxicity model group (benzbromarone 50 mg / kg), and groups receiving benzbromarone (50 mg / kg) first followed by Example 1 (450 mg / kg) after a 1-hour interval; groups receiving benzbromarone (50 mg / kg) first followed by Example 2 (450 mg / kg) after a 1-hour interval; and groups receiving benzbromarone (50 mg / kg) first followed by Example 3 (450 mg / kg) after a 1-hour interval. The total volume of each drug administered (the sum of the volumes of the two drugs) was 0.1 mL / 10 g. In the modeling and administration methods: the normal group was administered the same dose of 0.5% CMC-Na by gavage. Other groups were first administered potassium oxonate and adenine by gavage to establish a hyperuricemic nephropathy model. One hour later, they were administered 0.5% CMC-Na (normal group), 0.5% CMC-Na (HN model group), 0.5% CMC-Na (Example 1 group), benzbromarone (hepatotoxicity model group), benzbromarone (benzbromarone + Example 1 group), benzbromarone (benzbromarone + Example 2 group), and benzbromarone (benzbromarone + Example 3 group) by gavage. One hour later, they were administered 0.5% CMC-Na (normal group), 0.5% CMC-Na (HN model group), the composition of Example 1 (Example 1 group), 0.5% CMC-Na (hepatotoxicity model group), the composition of Example 1 (benzbromarone + Example 1 group), the composition of Example 2 (benzbromarone + Example 2 group), and the composition of Example 3 (benzbromarone + Example 3 group) by gavage again. The above modeling and drug administration procedures were repeated daily. Every 7 days (days 7, 14, 21, and 28 of the experiment), blood was collected from the orbital cavity 2 hours after the last gavage administration.

[0122] (2) Effects of combined drug therapy on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels

[0123] The indicators were measured using: Alanine aminotransferase (ALT) assay kit (catalog number: C009-1-1; Reitman method), Nanjing Jiancheng Biotechnology Co., Ltd.; Aspartate aminotransferase (AST) assay kit (catalog number: C010-2-1; microplate method), Nanjing Jiancheng Biotechnology Co., Ltd.

[0124] Table 4. Effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum AST levels (U / L)

[0125]

[0126] Note: Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences, *P<0.05, indicating significant statistical differences; Compared with the liver injury group (benzbromarone administration group): ###P<0.01, ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0127] Table 5. Effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum ALT levels (U / L)

[0128]

[0129] Note: Compared with the normal group: ***P<0.001, **P<0.01, indicating extremely significant statistical differences; compared with the liver injury group (benzbromarone administration group): ###P<0.01, ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0130] like Figure 4 , Figure 5As shown in Tables 4 and 5, serum AST and ALT levels in the benzbromarone group were significantly higher than those in the normal group from the first and second weeks onwards (P<0.05, P<0.01, P<0.001). AST and ALT levels in rats treated alone with the composition of Example 1 tended to normalize (compared to the normal group). The combined treatment groups significantly inhibited the increase in AST levels induced by benzbromarone, with statistically significant differences compared to the benzbromarone group (P<0.05, P<0.01, or P<0.001). The combined treatment groups showed hepatoprotective effects from the first week, with AST levels tending to normalize by the fourth week. Furthermore, the combined treatment groups significantly inhibited the increase in ALT levels induced by benzbromarone, with statistically significant differences compared to the benzbromarone group (P<0.05, P<0.01, or P<0.001). The combined treatment groups showed hepatoprotective effects from the first week.

[0131] The results showed that the combined use of the traditional Chinese medicine composition and benzbromarone could reduce liver damage induced by benzbromarone. Compared with the liver injury group (benzbromarone administration group), the differences were statistically significant: ###P<0.01, ##P<0.01 (extremely significant difference), and #P<0.05 (significant difference), indicating that the combined use of the medicine enhanced the hepatoprotective effect compared with benzbromarone alone.

[0132] Example 3

[0133] The synergistic effect of the traditional Chinese medicine composition combined with benzbromarone is as follows:

[0134] In vivo animal experiments have demonstrated that the combined use of traditional Chinese medicine and benzbromarone significantly increases the uric acid-lowering efficacy in rats with hyperuricemia nephropathy induced by potassium oxonate and adenine, compared with the use of benzbromarone alone.

[0135] (1) Experimental design of synergistic effect

[0136] The effective dose of the traditional Chinese medicine composition in a rat model of chronic hyperuricemic nephropathy was 450 mg / kg or 900 mg / kg. The clinical dose of benzbromarone is 50 mg daily for adults (based on a body weight of 70 kg), which is equivalent to 4.5 mg / kg for rats.

[0137] Sixty-four SD rats were randomly divided into four groups of eight: a blank (NC) group, a hyperuricemic nephropathy model (HN) group, a benzbromarone group (4.5 mg / kg, administered in two divided doses), an Example 1 group (450 mg / kg, administered in two divided doses), an Example 1 group (2.25 mg / kg administered first, followed by Example 1 group (225 mg / kg) after a 1-hour interval), an Example 1 group (450 mg / kg) administered first, followed by Example 2 group (2.25 mg / kg) after a 1-hour interval, and an Example 3 group (225 mg / kg) administered first, followed by Example 3 group (225 mg / kg) after a 1-hour interval. The total volume of each drug administered (the sum of the volumes of the two drugs) was 0.1 mL / 10 g. Modeling and administration: The normal group was administered the same dose of 0.5% CMC-Na by gavage. Other groups were first administered potassium oxonate and adenine by gavage to establish a hyperuricemic nephropathy model. One hour later, they were administered 0.5% CMC-Na (normal group), 0.5% CMC-Na (HN model group), benzbromarone 2.25 mg / kg (benzbromarone 4.5 mg / kg group), and the composition of Example 1 225 mg / kg (Example 1) by gavage. The following groups were administered the following medications by gavage: 450 mg / kg group, benzbromarone 2.25 mg / kg (benzbromarone 2.25 mg / kg + Example 1 composition 225 mg / kg group), benzbromarone 2.25 mg / kg (benzbromarone 2.25 mg / kg + Example 1 composition 450 mg / kg group), benzbromarone 2.25 mg / kg (benzbromarone 2.25 mg / kg + Example 2 composition 225 mg / kg group), benzbromarone 2.25 mg / kg (benzbromarone 2.25 mg / kg + Example 3 composition 225 mg / kg group). One hour later, they were again administered 0.5% CMC-Na (normal group), 0.5% CMC-Na (HN model group), benzbromarone 2.25 mg / kg (benzbromarone 4.5 mg / kg group), and Example 1 composition 225 mg / kg (Example 1... The following groups were used: 450 mg / kg group, Example 1 composition 225 mg / kg (benzbromarone 2.25 mg / kg + Example 1 composition 225 mg / kg group), Example 1 composition 450 mg / kg (benzbromarone 2.25 mg / kg + Example 1 composition 450 mg / kg group), Example 2 composition 225 mg / kg (benzbromarone 2.25 mg / kg + Example 2 composition 225 mg / kg group), and Example 3 composition 225 mg / kg (benzbromarone 2.25 mg / kg + Example 3 composition 225 mg / kg group). The above modeling and drug administration procedures were repeated daily. Blood samples were collected from the orbital sinus 2 hours after the last gavage administration on days 7 and 14. Serum was separated, and uric acid levels were measured.

[0138] (2) Effects of combined drug therapy on serum uric acid levels

[0139] Table 6. Effects of the traditional Chinese medicine compositions combined with benzbromarone in Examples 1-3 on serum uric acid levels (mg / L)

[0140]

[0141] Note: Compared with the normal group: ***P<0.001; Compared with the hyperuricemia model group: ###P<0.01, ##P<0.01, indicating extremely significant statistical differences, #P<0.05, indicating significant statistical differences.

[0142] like Figure 6 As shown in Table 6, serum uric acid levels in the model group were significantly higher than those in the control group at the beginning of the first week (P<0.001), proving the successful establishment of the hyperuricemia model. In the first week, benzbromarone (4.5 mg / kg) did not show any efficacy. However, the combined treatment groups (benzbromarone 2.25 mg / kg + traditional Chinese medicine composition 225 mg / kg or 450 mg / kg) all showed varying degrees of uric acid-lowering trends (but there was no statistically significant difference compared to the model group, P>0.05). In the second week, benzbromarone (4.5 mg / kg) showed some efficacy (compared to the model group, P=0.069). The combined treatment groups (benzbromarone 2.25 mg / kg + traditional Chinese medicine composition 225 mg / kg or 450 mg / kg) all showed significant uric acid-lowering effects (compared to the model group, P<0.01), and the average uric acid level in the combined treatment group was lower than that in the benzbromarone-only treatment group. In the third week, benzbromarone (4.5 mg / kg) showed significant efficacy (P<0.05 compared to the model group). The combination therapy groups (benzbromarone 2.25 mg / kg + traditional Chinese medicine composition 225 mg / kg or 450 mg / kg) all showed significant uric acid-lowering effects (P<0.05 or P<0.001 compared to the model group), and the average uric acid level in the combination therapy groups was lower than that in the benzbromarone-only groups. Therefore, the traditional Chinese medicine composition enhances the uric acid-lowering activity of benzbromarone. Combination therapy can maintain or even improve efficacy even with a halved benzbromarone dose.

[0143] Furthermore, according to Bürgi's formula (Dai Tijun, Quantitative Analysis of Combined Drug Use, Chinese Journal of Pharmacology, 1998, 14(5); 479-480.): q=E( A / 2 + B / 2 ) / E A (or E) B ), where E A E B The effects of using A and B alone are respectively, and E A =EB E( A / 2 + B / 2 The effect is the combined effect of taking half of A and half of B. q > 1 indicates enhancement, q = 1 indicates additive effect, and q < 1 indicates antagonism. In this invention, as... Figure 6 As shown, in the third week, benzbromarone (4.5 mg / kg) and the traditional Chinese medicine combination (450 mg / kg) showed similar efficacy (uric acid inhibition rates of 41.3% and 42.7%, respectively). The combined use of halved doses (benzbromarone 2.25 mg / kg + traditional Chinese medicine combination 225 mg / kg) showed significantly higher efficacy (uric acid inhibition rates of 52.2%, 49.3%, and 50.3%, respectively). The q-values ​​(compared to benzbromarone) were 1.3, 1.2, and 1.2, respectively, and the q-values ​​(compared to the traditional Chinese medicine combination) were 1.2, 1.2, and 1.2, respectively. All q-values ​​were greater than 1, indicating a synergistic effect.

[0144] The results above show that the traditional Chinese medicine composition of the present invention can effectively reduce liver damage caused by benzbromarone and enhance the uric acid-lowering activity of benzbromarone.

[0145] In summary, the herbal composition of this invention can effectively treat hyperuricemia, and when used in combination with benzbromarone, it can enhance the uric acid-lowering activity and reduce liver damage caused by benzbromarone use, providing a new option for clinical practice.

Claims

1. A kit for treating chronic hyperuricemia or hyperuricemic nephropathy, characterized in that, It is made of medicine box A and medicine box B, wherein medicine box A is a traditional Chinese medicine composition and medicine box B is benzbromarone; The mass ratio of medicine box A to medicine box B is 100:1; The content of active ingredients in the traditional Chinese medicine composition is more than 50%, where the percentage is a mass percentage; The active ingredients of the traditional Chinese medicine composition include: apigenin, luteolin, luteolin-4'-O-glucoside, gingerol, quercetin, caffeic acid, methyl caffeate, and gnaphaffine. A, methyl 3,5-di-O-caffeoylquinic acid, 3,4,5-tri-O-caffeoylquinic acid, methyl 1,4-di-O-caffeoylquinic acid, 1,3,5-tri-O-caffeoylquinic acid, 1,3,4-tri-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, 3,4-di-O-caffeoylquinic acid, 1,4-di-O-caffeoylquinic acid, 1-O-caffeoylglucose, 4,6,4'-trihydroxy-2-methoxychalcone, 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside, chlorogenic acid, 5-O-caffeoylquinic acid and ethyl caffeate; The traditional Chinese medicine composition is prepared by the following method, which includes the following steps: S1. Mix cudweed with an ethanol-water solution and extract to obtain an extract; Wherein, the ethanol aqueous solution is an ethanol aqueous solution with a volume percentage of 50% to 80%; S2. Concentrate the extract to obtain a concentrated solution; S3. Extract the concentrate with petroleum ether to obtain aqueous phase one; extract aqueous phase one with ethyl acetate to obtain aqueous phase two and ethyl acetate phase; extract aqueous phase two with water-saturated n-butanol to obtain water-saturated n-butanol phase; collect the ethyl acetate phase and the water-saturated n-butanol phase; The preparation method further includes: S4. concentrating and drying the mixture of the ethyl acetate phase and the water-saturated n-butanol phase under reduced pressure; or concentrating and drying the ethyl acetate phase and the water-saturated n-butanol phase under reduced pressure and then mixing them; The temperature for vacuum concentration is 40~80℃.

2. The medicine box as described in claim 1, characterized in that, In S1, the ethanol aqueous solution is an ethanol aqueous solution with a volume percentage of 60%; And / or, in S1, the mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10~1:20 kg / L; And / or, in S1, the cudweed is cudweed that has been dried in the shade; And / or, in S1, the extraction temperature is 50~100℃; And / or, in S1, the number of extractions is 2 to 4; and the time for a single extraction is 1 to 2 hours. And / or, in S2, the concentration temperature is 50~70°C; And / or, in S2, the mass-to-volume ratio of the cudweed described in S1 to the concentrated liquid described in S2 is 1:0.5~1:2 kg / L.

3. The medicine box as described in claim 2, characterized in that, In S1, the mass-to-volume ratio of the cudweed to the ethanol aqueous solution is 1:10~1:15 kg / L.

4. The medicine box as described in claim 2, characterized in that, In S1, the extraction temperature is 70~100℃.

5. The medicine box as described in claim 2, characterized in that, The mass-to-volume ratio of the cudweed in S1 to the concentrated liquid in S2 is 1:0.5~1:1 kg / L.

6. The medicine box as described in claim 1, characterized in that, In S3, the volume ratio of the concentrate to the petroleum ether is 1:1 to 1:

2. And / or, in S3, the petroleum ether extraction is performed 2 to 4 times; And / or, in S3, the petroleum ether is a petroleum ether with a boiling range of 60~90℃; And / or, in S3, the volume ratio of the aqueous phase I to the ethyl acetate is 1:1 to 1:2; And / or, in S3, the ethyl acetate extraction is performed 2 to 4 times; And / or, in S3, the volume ratio of the aqueous phase II to the water-saturated n-butanol is 1:1 to 1:2; And / or, in S3, the water-saturated n-butanol extraction is performed 2 to 4 times.

7. The medicine box as described in claim 1, characterized in that, The active ingredient content of the traditional Chinese medicine composition is 54.12%~57.81%; All percentages are mass percentages.

8. The medicine box as described in claim 1, characterized in that, The active ingredients of the traditional Chinese medicine composition include: 0.1%~5.5% apigenin, 0.5%~9.8% luteolin, 0.2%~10.0% luteolin-4'-O-glucoside, 0.01%~2.2% galangin, 0.02%~1.4% quercetin, 0.8%~3.9% caffeic acid, 0.1%~13.0% methyl caffeate, and 0.1%~3.3% gnaphaffine. A. 0.01%~0.8% of methyl 3,5-di-O-caffeoylquinic acid, 0.2%~10.4% of 3,4,5-tri-O-caffeoylquinic acid, 0.01%~0.5% of methyl 1,4-di-O-caffeoylquinic acid, 0.03%~9.5% of 1,3,5-tri-O-caffeoylquinic acid, 0.2%~12.8% of 1,3,4-tri-O-caffeoylquinic acid, 0.3%~6.5% of 3,5-di-O-caffeoylquinic acid, 0.1%~5.2% of 3,4-di-O-caffeoylquinic acid... The ingredients include caffeoylquinic acid, 0.1%–7.6% of 1,4-di-O-caffeoylquinic acid, 1.5%–3.7% of 1-O-caffeoyl glucose, 0.06%–5.2% of 4,6,4'-trihydroxy-2-methoxychalcone, 0.1%–3.8% of 4,6,4'-trihydroxy-2-methoxychalcone-4-O-glucoside, 0.2%–2.9% of chlorogenic acid, 0.4%–4.1% of 5-O-caffeoylquinic acid, and 0.1%–1.5% of ethyl caffeate; all percentages are by mass.

9. The medicine box as described in claim 1, characterized in that, Use medicine box A first and then use medicine box B, or use medicine box B first and then use medicine box A.

10. The use of a kit as described in any one of claims 1 to 9 in the preparation of a medicament for treating chronic hyperuricemia or hyperuricemic nephropathy.

11. The use of the kit as described in claim 10 in the preparation of a medicament for treating chronic hyperuricemia or hyperuricemic nephropathy, characterized in that, When the aforementioned medicine box is in use, the daily dosage of medicine box B is 0.35~0.72mg / kg; And / or, when the kit is in use, the daily dosage of kit A is 35~143 mg / kg.

Citation Information

Patent Citations

  • Plant-origin drug for preventing or improving hyperuricemia

    CN101925361A

  • Gnaphalium affine extract, gnaphalium affine active substance enriched product, preparation method and application

    CN107126450A